FATE THERAPEUTICS INC Variable Lease, Cost
FATE THERAPEUTICS INC (FATE) reported Variable Lease, Cost of $3.19 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-26
- FATE THERAPEUTICS INC variable lease, cost for the quarter ending 2024-03-31 was $887.00K, a 44.70% increase year-over-year.
- FATE THERAPEUTICS INC variable lease, cost for the quarter ending 2023-12-31 was $672.00K, a 4.55% decline year-over-year.
- FATE THERAPEUTICS INC variable lease, cost for the quarter ending 2023-09-30 was $467.00K, a 24.07% decline year-over-year.
- FATE THERAPEUTICS INC variable lease, cost for the quarter ending 2023-06-30 was $498.00K, a 26.55% decline year-over-year.
- FATE THERAPEUTICS INC variable lease, cost for fiscal 2025 was $3.19M, a 14.65% decline from fiscal 2024.
- FATE THERAPEUTICS INC variable lease, cost for fiscal 2024 was $3.73M, a 65.91% increase from fiscal 2023.
- FATE THERAPEUTICS INC variable lease, cost for fiscal 2023 was $2.25M, a 13.93% decline from fiscal 2022.
- FATE THERAPEUTICS INC variable lease, cost for fiscal 2022 was $2.61M, a 57.47% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 3 month as first filed | Variable Lease, Cost 6 month | Variable Lease, Cost 6 month as first filed | Variable Lease, Cost 9 month | Variable Lease, Cost 9 month as first filed | Variable Lease, Cost 12 month | Variable Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $3.19M 10-K · filed 2026-02-26 | |||||||
| 2024-12-31 | $3.73M 10-K · filed 2026-02-26 | |||||||
| 2024-03-31 | $887.00K 10-Q · filed 2024-05-09 | $1.56M derived: sum of 2 quarters · filed 2025-03-05 | $2.03M derived: sum of 3 quarters · filed 2025-03-05 | $2.52M derived: sum of 4 quarters · filed 2025-03-05 | ||||
| 2023-12-31 | $672.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $1.14M derived: sum of 2 quarters · filed 2025-03-05 | $1.64M derived: sum of 3 quarters · filed 2025-03-05 | $2.25M 10-K · filed 2025-03-05 | ||||
| 2023-09-30 | $467.00K 10-Q · filed 2023-11-08 | $965.00K derived: sum of 2 quarters · filed 2023-11-08 | $1.58M 10-Q · filed 2023-11-08 | $2.28M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2023-06-30 | $498.00K 10-Q · filed 2023-08-08 | $1.11M 10-Q · filed 2023-08-08 | $1.81M derived: sum of 3 quarters · filed 2024-05-09 | $2.43M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2023-03-31 | $613.00K 10-Q · filed 2024-05-09 | $1.32M derived: sum of 2 quarters · filed 2024-05-09 | $1.93M derived: sum of 3 quarters · filed 2024-05-09 | $2.61M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $704.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $1.32M derived: sum of 2 quarters · filed 2024-02-26 | $2.00M derived: sum of 3 quarters · filed 2024-02-26 | $2.61M 10-K · filed 2024-02-26 | ||||
| 2022-09-30 | $615.00K 10-Q · filed 2023-11-08 | $1.29M derived: sum of 2 quarters · filed 2023-11-08 | $1.91M 10-Q · filed 2023-11-08 | $2.45M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $678.00K 10-Q · filed 2023-08-08 | $1.29M 10-Q · filed 2023-08-08 | $1.84M derived: sum of 3 quarters · filed 2023-08-08 | $2.37M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | $618.00K 10-Q · filed 2023-05-03 | $1.16M derived: sum of 2 quarters · filed 2023-05-03 | $1.69M derived: sum of 3 quarters · filed 2023-05-03 | $2.04M derived: sum of 4 quarters · filed 2023-05-03 | ||||
| 2021-12-31 | $540.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.07M derived: sum of 2 quarters · filed 2023-02-28 | $1.43M derived: sum of 3 quarters · filed 2023-02-28 | $1.66M 10-K · filed 2023-02-28 | ||||
| 2021-09-30 | $529.00K 10-Q · filed 2022-11-03 | $885.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.12M 10-Q · filed 2022-11-03 | $1.73M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $356.00K 10-Q · filed 2022-08-03 | $591.00K 10-Q · filed 2022-08-03 | $1.20M derived: sum of 3 quarters · filed 2023-02-28 | $1.81M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $235.00K 10-Q · filed 2022-05-04 | $847.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.46M derived: sum of 3 quarters · filed 2023-02-28 | $1.87M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $612.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.22M derived: sum of 2 quarters · filed 2023-02-28 | $1.64M derived: sum of 3 quarters · filed 2023-02-28 | $2.25M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $608.00K 10-Q · filed 2021-11-04 | $1.02M derived: sum of 2 quarters · filed 2021-11-04 | $1.63M 10-Q · filed 2021-11-04 | $2.22M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $415.00K 10-Q · filed 2021-08-04 | $1.02M 10-Q · filed 2021-08-04 | $1.61M derived: sum of 3 quarters · filed 2022-02-28 | $2.20M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $610.00K 10-Q · filed 2021-05-05 | $600.00K 10-Q · filed 2020-05-11 | $1.20M derived: sum of 2 quarters · filed 2022-02-28 | $1.79M derived: sum of 3 quarters · filed 2022-02-28 | $2.35M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $587.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.18M derived: sum of 2 quarters · filed 2022-02-28 | $1.74M derived: sum of 3 quarters · filed 2022-02-28 | $2.33M 10-K · filed 2022-02-28 | $2.30M 10-K · filed 2020-03-02 | |||
| 2019-09-30 | $589.00K 10-Q · filed 2020-11-05 | $600.00K 10-Q · filed 2019-11-05 | $1.16M derived: sum of 2 quarters · filed 2020-11-05 | $1.74M 10-Q · filed 2020-11-05 | $1.80M 10-Q · filed 2019-11-05 | |||
| 2019-06-30 | $567.00K 10-Q · filed 2020-08-05 | $600.00K 10-Q · filed 2019-08-06 | $1.15M 10-Q · filed 2020-08-05 | $1.10M 10-Q · filed 2019-08-06 | ||||
| 2019-03-31 | $600.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |